Treatment of Elderly Patients with Higher Risk Myelodysplastic Syndromes with Oral Azacitidine

被引：0
|
作者：
Santini, Valeria [1 ]
Amato, Cristina [1 ]
De Pourcq, Sven [2 ]
della Seta, Roberta [3 ]
Caciagli, Barbara [1 ]
Raddi, Marco Gabriele [1 ]
Consagra, Angela [1 ]
Rigodanza, Luca [1 ]
Mattiuz, Giorgio [2 ]
Defina, Marzia [4 ]
Galimberti, Sara [5 ]
Maestrini, Giacomo [6 ]
Sanna, Alessandro [7 ]
机构：
[1] Univ Florence, MDS Unit, DMSC, AOU Careggi, Florence, Italy
[2] Univ Florence, MDS Unit, DMSC, Florence, Italy
[3] Azienda Osped Toscana Nord Ovest, Hematol, Massa Carrara, Italy
[4] Azienda Osped Univ Senese, Hematol, Siena, Italy
[5] Univ Pisa, Dept Clin & Expt Med, Hematol, Pisa, Italy
[6] AOU Toscana Ctr, Hematol, Florence, Italy
[7] AOU Careggi, Hematol, Florence, Italy
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-190016
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Efficacy, safety, and pharmacokinetics of subcutaneous azacitidine in Taiwanese patients with higher-risk myelodysplastic syndromes
    Chou, Wen-Chien
    Yeh, Su-Peng
    Hsiao, Liang-Tsai
    Lin, Sheng-Fung
    Chen, Yeu-Chin
    Chen, Tsai-Yun
    Laille, Eric
    Galettis, Anoula
    Dong, Qian
    Songer, Steve
    Beach, C. L.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 (05) : E430 - E439
  • [22] Phase I Combination Trial of Lenalidomide and Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes
    Sekeres, Mikkael A.
    List, Alan F.
    Cuthbertson, David
    Paquette, Ronald
    Ganetsky, Rebecca
    Latham, Deborah
    Paulic, Katarina
    Afable, Manuel
    Saba, Hussain I.
    Loughran, Thomas P., Jr.
    Maciejewski, Jaroslaw P.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (13) : 2253 - 2258
  • [23] Treatment of myelodysplastic syndromes with azacitidine and thalidomide
    Kenealy, M. K.
    Seymour, J. F.
    LEUKEMIA RESEARCH, 2007, 31 : S7 - S8
  • [24] The Effects of Continued Azacitidine (AZA) Treatment Cycles on Response in Higher-Risk Patients (Pts) with Myelodysplastic Syndromes (MDS)
    Silverman, Lewis R.
    Fenaux, Pierre
    Mufti, Ghulam J.
    Santini, Valeria
    Hellstrom-Lindberg, Eva
    Gattermann, Norbert
    Sanz, Guillermo
    List, Alan F.
    Gore, Steven D.
    Seymour, John F.
    Backstrom, Jay
    McKenzie, David
    Beach, C. L.
    BLOOD, 2008, 112 (11) : 91 - 91
  • [25] Pre- and post-treatment serum ferritin levels in patients with higher risk myelodysplastic syndromes receiving azacitidine
    Tsang, Erica
    Leitch, Heather A.
    LEUKEMIA & LYMPHOMA, 2016, 57 (11) : 2709 - 2711
  • [26] The role of azacitidine in the treatment of myelodysplastic syndromes
    Abdulhaq, Haifaa
    Rossetti, James M.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2007, 16 (12) : 1967 - 1975
  • [27] Treatment of myelodysplastic syndromes in elderly patients
    Sanchez J.F.
    Advances in Therapy, 2011, 28 (Suppl 2) : 1 - 9
  • [28] AZACITIDINE: AN ALTERNATIVE TREATMENT REGIMEN FOR ELDERLY HIGH-RISK MYELODYSPLASTIC PATIENTS
    Ramakrishna, R.
    Alexander, W.
    Sarathy, K.
    HAEMATOLOGICA, 2013, 98 : 583 - 584
  • [29] Azacitidine with Oral Cytarabine and Etoposide Induces Immediate Hematological and Cytogenetic Response in Higher Risk Myelodysplastic Syndromes Even in Single Azacitidine Resistance
    Matsuoka, Akihito
    Tanibuchi, Masaki
    Kadowaki, Norimitsu
    Taoka, Teruhisa
    BLOOD, 2015, 126 (23)
  • [30] COMBINATION OF ORAL RIGOSERTIB AND INJECTABLE AZACITIDINE IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS)
    Navada, S.
    Garcia-Manero, G.
    Hearn, K.
    Odchimar-Reissig, R.
    Demakos, E.
    Fenaux, P.
    Petrone, M.
    Zbyszewski, P.
    Fruchtman, S.
    Silverman, L.
    LEUKEMIA RESEARCH, 2017, 55 : S30 - S30
12345